Insulin Victoza and the future

Insulin Victoza and the future

Lost in all the excitement directed towards Ozempic, Wegovy, Mounjaro and Zepbound are what lies ahead for Lilly and Novo Nordisk when it comes to insulin. Also playing into this mix is the pending patent expiration of Victoza. The questions are,

1. How long will Lilly and Novo remain in the insulin business?

2. With a biosimilar of Victoza on the way how will that impact sales of Ozempic, Wegovy, Mounjaro and Zepbound?

The first question is the most difficult to answer. As we all know insulin has become a commodity and volume is everything. We . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.